Headlines about AMAG Pharmaceuticals (NASDAQ:AMAG) have been trending somewhat positive this week, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. AMAG Pharmaceuticals earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave news coverage about the specialty pharmaceutical company an impact score of 47.0967912981467 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news articles that may have impacted Accern Sentiment’s rankings:
- Leerink Swann Begins Coverage on AMAG Pharmaceuticals (AMAG) (americanbankingnews.com)
- $158.58 Million in Sales Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter (americanbankingnews.com)
- -$0.22 EPS Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter (americanbankingnews.com)
- B. Riley Comments on AMAG Pharmaceuticals, Inc.’s FY2018 Earnings (AMAG) (americanbankingnews.com)
- B. Riley Weighs in on AMAG Pharmaceuticals, Inc.’s FY2022 Earnings (AMAG) (americanbankingnews.com)
Shares of NASDAQ AMAG opened at $24.10 on Tuesday. The company has a quick ratio of 1.48, a current ratio of 1.57 and a debt-to-equity ratio of 0.97. AMAG Pharmaceuticals has a 12 month low of $11.93 and a 12 month high of $24.92. The company has a market cap of $846.15 million, a PE ratio of -4.22 and a beta of 0.10.
AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings data on Thursday, May 3rd. The specialty pharmaceutical company reported ($1.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($1.10). AMAG Pharmaceuticals had a negative net margin of 35.17% and a negative return on equity of 1.15%. The firm had revenue of $146.40 million during the quarter, compared to analyst estimates of $149.13 million. During the same period in the prior year, the company earned ($1.06) earnings per share. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. research analysts expect that AMAG Pharmaceuticals will post -3.4 EPS for the current year.
AMAG has been the topic of several recent analyst reports. BidaskClub raised AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, May 9th. Leerink Swann initiated coverage on AMAG Pharmaceuticals in a research report on Monday. They set a “market perform” rating and a $24.65 price target on the stock. Cantor Fitzgerald reaffirmed a “hold” rating and set a $17.00 price target on shares of AMAG Pharmaceuticals in a research report on Tuesday, February 27th. Piper Jaffray Companies reaffirmed a “neutral” rating on shares of AMAG Pharmaceuticals in a research report on Thursday, February 15th. Finally, ValuEngine raised AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, February 28th. Ten research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. AMAG Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $23.97.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.